Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | LSS | P48449 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29197658 | 0.88 | ESR2 (0.55) | ESR2NR1H2NAMPTSMN1; SMN2MAPK1 | |
| SCHEMBL19459096 | 0.87 | ESR2 (0.45) | ESR2NR1H2NAMPTMKNK1MAPK1 | |
| SCHEMBL22944628 | 0.87 | NAMPT (0.48) | ESR2NR1H2NAMPTMAPK1PTPN2 | |
| SCHEMBL28835616 | 0.87 | NR1H2 (0.56) | ESR2NR1H2NAMPTHTTMAPK1 | |
| SCHEMBL6352947 | 0.86 | MAPK1 (0.49) | ESR2NR1H2NAMPTMAPK1PDK4 | |
| SCHEMBL3986657 | 0.86 | ESR2 (0.45) | MEN1KMT2AESR2STSNR1H2 | |
| SCHEMBL21425206 | 0.85 | MAPT (0.50) | ESR2STSNR1H2NAMPTMAPK1 | |
| SCHEMBL22441484 | 0.84 | GRM1 (0.48) | ESR2NR1H2NAMPTMAPK1PDK4 | |
| SCHEMBL24323027 | 0.84 | CHRNB2 (0.56) | MEN1KMT2AESR2NR1H2MAPK1 | |
| SCHEMBL29497189 | 0.84 | CHRNB2 (0.56) | MEN1KMT2AESR2NR1H2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| WO-2022251280-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| EP-3778588-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20210032219-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | JAK2, JAK1, JAK3 | MEN1 3479/4885KMT2A 1674/4885ESR2 1628/4885 |
| US-20210032219-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | F2, PCSK9, F9 | MEN1 573/4885KMT2A 1893/4885ESR2 3215/4885 |
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | F2, PCSK9, F9 | MEN1 573/4885KMT2A 1893/4885ESR2 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.